Exponent vs Public Policy
EXPO and PPHC side by side, both in management and public relations services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EXPO and PPHC compare
Exponent is the larger company, worth 15 times as much as Public Policy ($4.2B against $280M).
Public Policy grew revenue faster over the last twelve months (24.7% versus 12.8% for Exponent).
Exponent keeps more of each dollar of sales as profit, with a net margin of 17.7% compared with −20.9% at Public Policy.
Both pay dividends: Exponent yields 1.4% and Public Policy 3.9%.
Exponent scores higher on the StockData Score (20 against 6 for Public Policy), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EXPO | PPHC |
|---|---|---|
| Size and price | ||
| Market cap | $4.2B | $280M |
| Share price | $89.16 | $9.25 |
| Change, 1 year | 30.8% | – |
| Change, 5 years | −23.6% | – |
| Beta (5Y) | 0.83 | – |
| Employees | 1,313 | 450 |
| StockData Score | ||
| Total score | 20 (better) | 6 |
| Valuation score | 2 (better) | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 5 (better) | 0 |
| Health score | 6 (better) | 3 |
| Dividend score | 4 (better) | 2 |
| Valuation | ||
| P/E | 40.0× | – |
| P/S | 6.7× | 1.5× (better) |
| P/B | 14.7× | 2.5× (better) |
| EV/EBITDA | 30.3× | – |
| P/FCF | 39.1× | 11.3× (better) |
| PEG | 21.77 | – |
| FCF yield | 2.6% | 8.9% (better) |
| Fair value | $64.47 | $6.49 |
| Margin of safety | −38.3% (better) | −42.6% |
| Growth | ||
| Revenue growth (TTM) | 12.8% | 24.7% (better) |
| Revenue growth, 5Y average | 7.8% | – |
| Net income growth (TTM) | 8.7% | – |
| EPS growth (TTM) | 11.5% | – |
| EPS growth, 5Y average | 6.0% | – |
| Profitability | ||
| Gross margin | – | 10.0% |
| Operating margin | 20.2% (better) | −18.2% |
| Net margin | 17.7% (better) | −20.9% |
| FCF margin | 17.2% (better) | 13.3% |
| Return on equity | 31.2% (better) | −40.6% |
| Return on invested capital | 43.8% (better) | −24.9% |
| Financial health | ||
| Debt / equity | 0.00 | 0.38 (better) |
| Interest coverage | – | −10.0× |
| Current ratio | 1.98 (better) | 1.60 |
| Altman Z-score | 10.38 (better) | 0.67 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | 1.4% | 3.9% (better) |
| Payout ratio | 54.8% | – |
| Years of dividend growth | 13 | – |
| Dividend growth, 5Y average | 9.6% | – |
| Buyback yield | 5.0% | – |
| Shareholder yield | 6.3% (better) | 3.9% |
| Ownership | ||
| Held by institutions | 97.8% | 22.7% |
| Held by insiders | 1.3% | 15.4% |
| Insider net buying, 12 months | −$2.7M | −$2.1M (better) |
| Short interest, % of float | 5.2% | 1.7% |
Go deeper
- EXPO stock overview
- EXPO income statement
- EXPO valuation and score
- PPHC stock overview
- PPHC income statement
- PPHC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.